RESUMEN
Exogenous metal particles and ions from implant devices are known to cause severe toxic events with symptoms ranging from adverse local tissue reactions to systemic toxicities, potentially leading to the development of cancers, heart conditions, and neurological disorders. Toxicity mechanisms, also known as Adverse Outcome Pathways (AOPs), that explain these metal-induced toxicities are severely understudied. Therefore, we deployed in silico structure- and knowledge-based approaches to identify proteome-level perturbations caused by metals and pathways that link these events to human diseases. We captured 177 structure-based, 347 knowledge-based, and 402 imputed metal-gene/protein relationships for chromium, cobalt, molybdenum, nickel, and titanium. We prioritized 72 proteins hypothesized to directly contact implant surfaces and contribute to adverse outcomes. Results of this exploratory analysis were formalized as structured AOPs. We considered three case studies reflecting the following possible situations: (i) the metal-protein-disease relationship was previously known; (ii) the metal-protein, protein-disease, and metal-disease relationships were individually known but were not linked (as a unified AOP); and (iii) one of three relationships was unknown and was imputed by our methods. These situations were illustrated by case studies on nickel-induced allergy/hypersensitivity, cobalt-induced heart failure, and titanium-induced periprosthetic osteolysis, respectively. All workflows, data, and results are freely available in https://github.com/DnlRKorn/Knowledge_Based_Metallomics/. An interactive view of select data is available at the ROBOKOP Neo4j Browser at http://robokopkg.renci.org/browser/.
Asunto(s)
Rutas de Resultados Adversos , Níquel , Humanos , Níquel/efectos adversos , Titanio/toxicidad , Metales/toxicidad , Cobalto , CromoRESUMEN
PEGylation is routinely used to extend the systemic circulation of various protein therapeutics and nanomedicines. Nonetheless, mounting evidence is emerging that individuals exposed to select PEGylated therapeutics can develop antibodies specific to PEG, i.e., anti-PEG antibodies (APA). In turn, APA increase both the risk of hypersensitivity to the drug as well as potential loss of efficacy due to accelerated blood clearance of the drug. Despite the broad implications of APA, the timescales and systemic specificity by which APA can alter the pharmacokinetics and biodistribution of PEGylated drugs remain not well understood. Here, we developed a physiologically based pharmacokinetic (PBPK) model designed to resolve APA's impact on both early- and late-phase pharmacokinetics and biodistribution of intravenously administered PEGylated drugs. Our model accurately recapitulates PK and biodistribution data obtained from PET/CT imaging of radiolabeled PEG-liposomes and PEG-uricase in mice with and without APA, as well as serum levels of PEG-uricase in humans. Our work provides another illustration of the power of high-resolution PBPK models for understanding the pharmacokinetic impacts of anti-drug antibodies and the dynamics with which antibodies can mediate clearance of foreign species.